eCite Digital Repository
Bevacizumab for metastatic colorectal cancer: A global cost-effectiveness analysis
Citation
Goldstein, DA and Chen, Q and Ayer, T and Chan, KKW and Virik, K and Hammerman, A and Brenner, B and Flowers, CR and Hall, PS, Bevacizumab for metastatic colorectal cancer: A global cost-effectiveness analysis, Oncologist, 22, (6) pp. 694-699. ISSN 1083-7159 (2017) [Refereed Article]
Copyright Statement
Copyright 2017 AlphaMed Press
DOI: doi:10.1634/theoncologist.2016-0455
Abstract
Background: In the U.S., the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer (mCRC) has been demonstrated to provide 0.10 quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio (ICER) of $571,000/QALY. Due to variability in pricing, value for money may be different in other countries. Our objective was to establish the cost-effectiveness of bevacizumab in mCRC in the U.S., U.K., Canada, Australia, and Israel.
Methods: We performed the analysis using a previously established Markov model for mCRC. Input data for efficacy, adverse events, and quality of life were considered to be generalizable and therefore identical for all countries. We used country-specific prices for medications, administration, and other health service costs. All costs were converted from local currency to U.S. dollars at the exchange rates in March 2016. We conducted one-way and probabilistic sensitivity analyses (PSA) to assess the model robustness across parameter uncertainties.
Results: Base case results demonstrated that the highest ICER was in the U.S. ($571,000/QALY) and the lowest was in Australia ($277,000/QALY). In Canada, the U.K., and Israel, ICERs ranged between $351,000 and $358,000 per QALY. PSA demonstrated 0% likelihood of bevacizumab being cost-effective in any country at a willingness to pay threshold of $150,000 per QALY.
Conclusion: The addition of bevacizumab to first-line chemotherapy for mCRC consistently fails to be cost-effective in all five countries. There are large differences in cost-effectiveness between countries. This study provides a framework for analyzing the value of a cancer drug from the perspectives of multiple international payers.
Implications for practice: The cost-effectiveness of bevacizumab varies significantly between multiple countries. By conventional thresholds, bevacizumab is not cost-effective in metastatic colon cancer in the U.S., the U.K., Australia, Canada, and Israel.
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | chemotherapy, colorectal cancer, cost, cost‐effectiveness, economics, value |
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Oncology and carcinogenesis |
Research Field: | Cancer therapy (excl. chemotherapy and radiation therapy) |
Objective Division: | Health |
Objective Group: | Clinical health |
Objective Field: | Clinical health not elsewhere classified |
UTAS Author: | Virik, K (Dr Kiran Virik) |
ID Code: | 126094 |
Year Published: | 2017 |
Web of Science® Times Cited: | 19 |
Deposited By: | Medicine |
Deposited On: | 2018-05-23 |
Last Modified: | 2018-09-11 |
Downloads: | 0 |
Repository Staff Only: item control page